McKesson stock lifts fiscal 2027 adjusted EPS outlook
Published on 11/05/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMcKesson raises fiscal outlook
- Fiscal second-quarter revenue rose 8 percent, with growth across all four operating segments.
- Management lifted the fiscal 2027 adjusted EPS range after stronger-than-expected first-half performance.
- Cash generation and share repurchases remain important indicators for the second half.
McKesson reported fiscal 2027 second-quarter results on November 4, with revenue growth across its operating segments and a higher full-year profit outlook. The company announced the results in its earnings release.
Profit growth broadens across segments
Revenue for the quarter ended September 30 reached 111.0 billion US dollars, up 8 percent from a year earlier. McKesson attributed the increase mainly to higher prescription volumes and specialty-product distribution in North American Pharmaceutical and Oncology & Multispecialty, while Prescription Technology Solutions also contributed to operating growth.
Adjusted earnings per diluted share rose 18 percent year over year to 11.68 US dollars. GAAP diluted earnings per share increased to 10.44 US dollars from 8.92 US dollars in the prior-year quarter. Management said the adjusted result reflected operating growth in several segments and a lower share count.
Guidance points to stronger second half
McKesson raised its fiscal 2027 adjusted earnings per diluted share guidance to 45.60 to 46.40 US dollars from 44.20 to 45.00 US dollars. The updated range implies reported adjusted EPS growth of 17 to 19 percent. Excluding the prior-year Norway divestiture contribution and gains linked to the US Oncology Network, management said growth would be 19 to 21 percent.
The company now expects fiscal-year revenue growth of 6 to 10 percent and adjusted operating-profit growth of 12 to 16 percent. It also generated 3.1 billion US dollars of operating cash flow and 2.9 billion US dollars of free cash flow during the quarter. Those figures leave cash conversion and capital allocation as key indicators for investors as the fiscal year progresses.
Quote and investor context
McKesson stock traded at 982.50 euros on Lang & Schwarz at 17:00:45 CET on Thursday, November 5, 2026. The real-time quote of McKesson stock is available separately.
McKesson Corporation
- Company: McKesson Corporation
- ISIN: US58155Q1031
- Fiscal second-quarter revenue: 111.0 billion US dollars, up 8 percent year over year
- Adjusted diluted EPS: 11.68 US dollars, up 18 percent year over year
- Fiscal 2027 adjusted EPS guidance: 45.60 to 46.40 US dollars
- Lang & Schwarz quote: 982.50 euros at 17:00:45 CET on November 5, 2026
The broader US market context is available in current S&P 500 market reports.
